Dyne Therapeutics (DYN) Accounts Payables (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Accounts Payables of $12.2 million for Q2 2026, down 13.29% year-over-year from $14.0 million in Q2 2025, and up 12.73% quarter-over-quarter from $10.8 million in Q1 2026.
Dyne Therapeutics (DYN) Accounts Payables (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Accounts Payables for 8 consecutive years, with $12.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accounts Payables fell 13.29% year-over-year to $12.2 million; the TTM figure through Jun 2026 stood at $12.2 million (down 13.29% YoY), while the FY2025 annual figure was $8.1 million, up 23.16% from the prior year.
- Accounts Payables grew to $12.2 million in Q2 2026 per DYN's latest filing, from $10.8 million in the prior quarter.
- Across five years, Accounts Payables topped out at $22.9 million in Q4 2023 and bottomed at $919000.0 in Q3 2022.
- Historically, Accounts Payables has averaged $7.9 million across 5 years, with a median of $7.0 million in 2022.
- Annual changes were most pronounced in 2022 — Accounts Payables plunged 87.03% — and 2025, when it soared 641.98%.
- Dyne Therapeutics' Accounts Payables stood at $5.3 million in 2022, then soared by 336.13% to $22.9 million in 2023, then tumbled by 71.39% to $6.6 million in 2024, then rose by 23.16% to $8.1 million in 2025, then surged by 50.37% to $12.2 million in 2026.
- Business Quant data shows DYN's Accounts Payables at $12.2 million in Q2 2026, $10.8 million in Q1 2026, and $8.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 12.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.15 Mn |
| Mar 31, 2026 | 10.78 Mn |
| Dec 31, 2025 | 8.08 Mn |
| Sep 30, 2025 | 12.06 Mn |
| Jun 30, 2025 | 14.02 Mn |
| Mar 31, 2025 | 7.02 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Sep 30, 2024 | 6.16 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | 7.21 Mn |
| Dec 31, 2023 | 22.94 Mn |
| Sep 30, 2023 | 3.55 Mn |
| Jun 30, 2023 | 2.72 Mn |
| Mar 31, 2023 | 8.77 Mn |
| Dec 31, 2022 | 5.26 Mn |
| Sep 30, 2022 | 919,000.00 |
| Jun 30, 2022 | 6.97 Mn |
| Mar 31, 2022 | 5.19 Mn |
| Dec 31, 2021 | 4.03 Mn |
| Sep 30, 2021 | 7.09 Mn |